



## Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

1.0  
NCPD

Chair: Beth Faiman, PhD, MSN, APN-BC, AOCN®

- 1.0 NCPD credit
- Pharmacotherapy credit
- ILNA points

Visiting Faculty Meeting

### STATEMENT OF NEED

Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. MM is primarily considered a disease of older adults, with a median age at diagnosis of 69 years. From 1975 to 2007, the incidence increased by 11.4%, and is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year survival rate remains only 52.2%.

### TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MM.

### LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Identify predictive and prognostic markers that can tailor treatment selection and goals to individual patients with MM
- Evaluate the efficacy and safety profiles of novel therapeutic strategies for newly diagnosed and relapsed/refractory MM
- Assess strategies to manage treatment-related adverse events, promote adherence to therapy, and ensure patient-centered MM care

Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.

### FACULTY

Beth Faiman, PhD, MSN, APN-BC, AOCN® (Chairperson)  
Nurse Practitioner, Department of Hematologic Oncology  
Cleveland Clinic Taussig Cancer Institute

Charise Gleason, MSN, NP-C, AOCNP®  
Advanced Practice Provider Chief  
Winship Cancer Institute of Emory University

Donna D. Catamero, ANP-BC, OCN®, CCRC  
Associate Director, Myeloma Translational Research  
The Mount Sinai Health System

Tiffany Richards, PhD, ANP-BC  
Advanced Practice Nurse  
MD Anderson Cancer Center

### ABOUT THE SPEAKER

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, is an adult nurse practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic Taussig Cancer Center in Cleveland, Ohio. She is also adjunct faculty at Kent State University, Ursuline College, and Case Western Reserve University. Dr. Faiman specializes in the treatment of hematologic disorders, including multiple myeloma, amyloidosis, chronic lymphocytic leukemia, and plasma cell cancer. She currently serves on the editorial board of *The Oncology Pharmacist* and *ASH Clinical News* and is Editor-in-Chief of *The Oncology Nurse APN/PA*. She is also an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. Dr. Faiman's research focuses on the treatment of blood disorders, and she has edited and authored numerous articles and book chapters on the management and palliation of cancer symptoms.

### ACCREDITATION

Jointly provided by

**USF Health**



USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity.

### REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Please note that USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

### INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

### REQUIREMENTS FOR CREDIT

Participants must sign-in before the start of the activity to verify attendance. All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required. At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed within two weeks of the activity.

## DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS

USF Health and i3 Health endorse the standards of the ANCC that require everyone in a position to control the content of an NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when individuals in a position to control the content of NCPD have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

USF Health will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.

Disclosures are on file at the University of South Florida, Office of Continuing Professional Development.

Relevant financial relationships exist between the following individuals and commercial interests:

- Beth Faiman, PhD, MSN, APN-BC, AOCN®, discloses that she has served on the advisory board/panel for Bristol Myers Squibb, Celgene Corporation, and Takeda. She has also served as a consultant for Bristol Myers Squibb and Celgene Corporation
- Charise Gleason, MSN, NP-C, AOCNP®, discloses that she has served as a consultant for Celgene
- Donna D. Catamero, ANP-BC, OCN®, CCRC, discloses that she has served as a consultant for Bristol Myers Squibb. She has also served on the advisory board/panel for Bristol Myers Squibb
- Tiffany Richards, PhD, ANP-BC, discloses that she has served on the advisory board/panel for Celgene, GlaxoSmithKline, and Takeda

The i3 Health planners and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.

## SUNSHINE ACT

Per the Physician Payments Sunshine Act, i3 Health is required by law to report to CMS any transfers of value (including food and beverage) provided to a covered recipient during a commercially supported educational event. Effective January 1, 2020, Physician Assistants, Nurse Practitioners, and Clinical Nurse Specialists are considered "covered recipients". All NPs and CNSs who would like to participate in the provided meal will be asked to provide all required information for reporting purposes.

## ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

## DOWNLOAD THE SPEAKER SLIDES

[i3Health.com/ons-multiple-myeloma](http://i3Health.com/ons-multiple-myeloma)

## COMMERCIAL SUPPORT

This activity is supported by independent educational grants from Celgene Corporation, Sanofi Genzyme, and Karyopharm Therapeutics. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

## DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

## UNAPPROVED USE DISCLOSURE

USF Health and i3 Health require NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

## AGENDA

- I. MM: Scope of the Problem
- II. Case Icebreaker: Tailoring Therapeutic Strategies to Individual Patients
- III. Essentials of Risk Adapted Therapy Selection
- IV. Update on Emerging Combination and Sequential Treatment Strategies for Newly Diagnosed and Relapsed/Refractory Disease
- V. Managing Adverse Events and Promoting Adherence to Therapy
- VI. Addressing Common Patient Questions About Their Prognosis and Treatment
- VII. Case Icebreaker: Optimizing Treatment Experiences and Ensuring Patient-Centered Care
- VIII. Educational Resources to Share With Patients With MM
- IX. Key Learning Takeaways/Participant Q&As

## AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or [support@i3Health.com](mailto:support@i3Health.com).

## CONTACT INFORMATION

Technical queries about this activity should be directed to [support@i3health.com](mailto:support@i3health.com).

Questions regarding activity credit should be directed to [cpdsupport@usf.edu](mailto:cpdsupport@usf.edu) or call (813) 224-7860.